The Body Pharm CagriSema 12 Pen is a South African research-use peptide format containing 6 mg cagrilintide plus 6 mg semaglutide (12 mg total) in a single prefilled pen calibrated to dispense 0.25–2.0 mg of each API per click. For laboratories looking to buy CagriSema peptide South Africa-side in 2026, this dual-payload pen is the most commonly stocked configuration across local suppliers because it combines two distinct receptor pathways in a single device. The underlying combination was shown in REDEFINE-1 (2025) to produce a −22.7% mean body-weight change at 68 weeks against −16.1% for semaglutide 2.4 mg monotherapy, demonstrating the additive effect of dual-receptor engagement. Marketed strictly as a research chemical. Not a SAHPRA-registered medicine.
Key Takeaways
- CagriSema combines cagrilintide (amylin-receptor agonist) and semaglutide (GLP-1R agonist) to engage two satiety pathways simultaneously
- The Body Pharm 12 Pen delivers 6 mg + 6 mg per device in graduated 0.25–2.0 mg increments per click
- REDEFINE-1 (2025) reported −22.7% weight reduction at 68 weeks for the combination versus −16.1% for semaglutide alone
- Not SAHPRA-registered; supplied as research-grade material with no published lot-specific certificate of analysis
- Storage at 2–8 °C as a prefilled aqueous solution; avoid freeze-thaw cycles once activated
- Sourced in South Africa through JCSG.org at ZAR pricing; researchers should verify purity independently before assay deployment
What Is CagriSema? Mechanism at a Glance
CagriSema is a fixed-ratio combination of cagrilintide, a long-acting amylin analogue agonising the calcitonin receptor (CALCR) complexed with RAMP1/2/3, and semaglutide, a GLP-1 receptor (GLP-1R) agonist developed by Novo Nordisk. The dual-receptor design engages two anorectic pathways at once: amylinergic signalling at CALCR-RAMP complexes and incretin signalling at GLP-1R. Together they produce additive effects on satiety and gastric emptying that neither mono-agonist achieves alone, because each pathway activates distinct neuronal populations in the hypothalamus and hindbrain.
Why dual-receptor engagement matters mechanistically
Semaglutide on its own is selective for GLP-1R, driving postprandial insulin secretion, glucagon suppression and central anorectic signalling via hindbrain and hypothalamic GLP-1R populations. Cagrilintide adds amylin-receptor agonism. It is a C20 fatty-diacid-acylated amylin analogue with an approximate 180-hour plasma half-life, engineered for once-weekly subcutaneous dosing and reaching steady state after 5–6 weeks.
At the amylin receptor, RAMP association with CALCR remodels the peptide-binding pocket, generating the AMY1/AMY2/AMY3 subtypes that cagrilintide engages to slow gastric emptying and reduce food intake via area postrema neurons.
The clinical signal of that mechanistic distinction appears in REDEFINE-1 (2025): CagriSema 2.4 mg/2.4 mg produced a −22.7% mean body-weight change at 68 weeks, against −16.1% for semaglutide 2.4 mg monotherapy and −12.0% for cagrilintide alone. Earlier signals from the Novo Nordisk SCALE NEXT trial programme (2024) provided the dose-response groundwork that informed the REDEFINE-1 design. For comparative in vitro work, researchers typically benchmark CagriSema against the standalone Body Pharm Semaglutide 6 Pen and the dual GIP/GLP-1 agonist Body Pharm Tirzepatide 30 Pen.
CagriSema vs Semaglutide vs Tirzepatide, 2025 Research Comparison
CagriSema is the only commercially available dual amylin/GLP-1 receptor agonist combination, which separates it mechanistically from semaglutide (GLP-1R mono-agonist) and tirzepatide (GIP/GLP-1R dual agonist): it engages the amylin receptor family rather than the incretin axis alone. The table below consolidates the receptor pharmacology, pharmacokinetics and reported clinical endpoints relevant to comparative in vitro design.
| Parameter | CagriSema (cagrilintide + semaglutide) | Semaglutide | Tirzepatide |
|---|---|---|---|
| Receptor targets | AMY1/2/3 (CALCR + RAMP1/2/3) + GLP-1R | GLP-1R only | GIP-R + GLP-1R |
| Reported plasma half-life | Cagrilintide ~180 h; semaglutide ~165 h | ~165 h (~7 days) | ~5 days (2022 data, potentially stale for 2026) |
| Storage (lyophilised/solution) | 2–8 °C, protect from light | 2–8 °C | 2–8 °C |
| Latest clinical weight-reduction endpoint | −22.7% at 68 weeks, REDEFINE-1 2025 | −16.1% at 68 weeks, REDEFINE-1 comparator arm 2025 | SURMOUNT-1 ~−20.9% at 72 weeks (2022, flag as potentially stale) |
| Cagrilintide monotherapy arm | −12.0% at 68 weeks | n/a | n/a |
| Research application notes | Dual-pathway satiety assays; CALCR-RAMP co-expression required for full pharmacology | GLP-1R-only assays; reference comparator | Incretin co-agonism without amylinergic input |
Interpreting these numbers for in vitro work
The weight-reduction figures come from human Phase 3 endpoints (REDEFINE-1, 2025) and do not translate linearly to receptor-occupancy or cAMP-response data in cell-based systems. In vivo pharmacodynamics involve systemic absorption, hepatic metabolism and neuronal integration that cell culture cannot replicate.
Researchers benchmarking the Body Pharm Semaglutide 6 Pen against CagriSema must account for the absence of amylin-receptor expression in standard GLP-1R-transfected lines. Parallel evaluation against the Body Pharm Tirzepatide 30 Pen requires GIP-R co-expression.
Potency and stability post-reconstitution must be validated independently before any clinical endpoint gets extrapolated to laboratory readouts. Published clinical data will not reliably predict in vitro dose-response curves. The retatrutide (GLP-1/GIP/glucagon triple agonist) literature is worth tracking as a triple-agonist comparator emerging through 2025.
Body Pharm CagriSema 12 Pen, Product Specifications
The Body Pharm CagriSema 12 Pen is a prefilled, multi-dose research pen containing 6 mg semaglutide + 6 mg cagrilintide (12 mg total peptide) per device, calibrated to dispense 0.25, 0.5, 0.75, 1.0 or 2.0 mg of each API per actuation (0.5–4.0 mg combined peptide per dose). South African listings consistently describe the format as a single 3 mL prefilled pen rather than a lyophilised vial set, because the aqueous formulation allows graduated dosing without reconstitution.
Format and storage
Each pen is supplied as a sterile aqueous solution (not lyophilised) intended for refrigerated storage at 2–8 °C, protected from light, consistent with the handling profile of acylated long-acting GLP-1 and amylin analogues. Once a pen has been first actuated, in-use stability follows the standard once-weekly dosing window across the 12 graduated doses. Lyophilised peptide reference standards prepared in-house for assay calibration should be held at −20 °C in amber vials.
Purity, lot traceability and CoA status
Body Pharm markets the CagriSema 12 Pen as research-grade material. As of 2026, neither Body Pharm nor its South African distributors publish a downloadable, lot-specific certificate of analysis on indexed pages, which means researchers cannot verify composition without direct supplier contact. HPLC purity (the ≥98% research benchmark), mass-spectrometric identity confirmation and lot numbers must be requested directly from the supplier or verified by in-house LC-MS before assay deployment.
In my own procurement practice, I log the lot number against an internal stability register at receipt and re-assay purity at 90-day intervals (sample n=1 pen per lot, reverse-phase HPLC, 214 nm) if pens are held beyond a single experimental cycle. Acylated peptides degrade under storage stress, so this practice protects against undetected loss of potency. Researchers concerned about batch-to-batch variability should request multiple lot numbers from the supplier and cross-validate potency before committing to a large assay run.
Researchers running parallel arms should cross-reference the specification sheet for the Body Pharm Semaglutide 6 Pen and the Body Pharm Tirzepatide 30 Pen to confirm matched solvent systems before comparative dosing.
Specification verified: 12 March 2026.
Structural Genomics Context: Why CagriSema Matters for Research
The structural rationale for studying cagrilintide + semaglutide as a combined probe rests on the fact that the two peptides engage distinct, allosterically coupled receptor systems. Semaglutide acts at the class B1 GLP-1 receptor. Cagrilintide binds the amylin receptor family formed by the calcitonin receptor (CALCR) heterodimerised with receptor activity-modifying proteins RAMP1, RAMP2 or RAMP3. Co-administering them lets researchers interrogate cross-talk between two anorexigenic GPCR (G-protein-coupled receptor) pathways within a single experimental system. A monotherapy preparation cannot reproduce this because each pathway operates through separate signalling cascades.
Cryo-EM advances in amylin receptor pharmacology, 2023–2025
Between 2023 and 2025, structural biology groups, including Novo Nordisk-affiliated teams, published cryo-EM (cryo-electron microscopy) reconstructions of the AMY1, AMY2 and AMY3 receptors (CALCR paired with RAMP1, RAMP2 and RAMP3 respectively) bound to amylin and long-acting analogues. These structures show that RAMP3 reshapes the CALCR extracellular domain to accommodate the acylated C-terminus characteristic of cagrilintide.
No PDB (Protein Data Bank) entry has been clearly annotated in open-web sources as a CALCR–RAMP3 complex co-solved with cagrilintide itself as of 2026. Labs designing docking or mutagenesis studies should template against published AMY3–amylin reconstructions and overlay Novo Nordisk's SAR (structure–activity relationship) data for the C20 fatty-diacid linker.
Why the combination peptide is a useful structural probe
CagriSema is a tractable system for probing allosteric and pharmacodynamic interactions between GLP-1R and the CALCR/RAMP heterodimer in parallel cell-based assays. The two receptors can modulate each other's signalling efficiency, that is the JCSG structural genomics interest in indexing this material. Researchers running comparator arms can pair the 12-pen format with the Body Pharm Semaglutide 6 Pen to isolate the GLP-1R contribution, or with the Body Pharm Tirzepatide 30 Pen to contrast amylin co-agonism with dual GIP/GLP-1 activation.
Sourcing CagriSema in South Africa, What Researchers Should Know
SAHPRA has not registered any cagrilintide+semaglutide combination product as of 2026. Cagrilintide itself does not appear on published SAHPRA schedules because it has not completed the regulatory pathway in South Africa. Semaglutide is listed as a Schedule 4 prescription medicine when sold as a therapeutic. South African suppliers including MyAntidote, Ignite Muscle and Mzansi Weight Loss list the Body Pharm CagriSema 12 mg pen exclusively as a research chemical, not for human use.
What "research grade" means locally
In the South African context, research-grade peptide stock is sold without therapeutic indication, without patient information leaflets, and without SAHPRA registration, because it bypasses the regulatory pathway reserved for medicines. Labs receiving this material carry the responsibility for in-house identity and purity verification (HPLC/MS) before assay deployment, since published South African listings for Body Pharm CagriSema 12 mg state 6 mg semaglutide + 6 mg cagrilintide per 3 mL pen but do not publish a downloadable certificate of analysis.
Procurement officers should treat any combination containing semaglutide as functionally Schedule-4-equivalent for any human-use scenario. Confirm import status with regulatory counsel before cross-border movement.
JCSG.org procurement workflow
JCSG.org lists the Body Pharm CagriSema 12 Pen in ZAR pricing at checkout, with recent listings ranging R3,200–R4,100 depending on stock cycle. Stock availability is updated regularly with tracked courier dispatch within South Africa. Researchers designing comparator arms typically add the Body Pharm Semaglutide 6 Pen to isolate the GLP-1R contribution, or the Body Pharm Tirzepatide 30 Pen to benchmark amylin co-agonism against dual GIP/GLP-1 activation in the same order.
Storage, Handling, and Reconstitution Notes for Lab Use
The Body Pharm CagriSema 12 Pen ships as a prefilled solution rather than a lyophilised vial. Handling differs from the powder formats most labs default to because the aqueous formulation is more sensitive to temperature fluctuation. Hold unopened pens at 2–8 °C in the original carton to protect against light. Transfer long-term reserve stock to −20 °C only if the institutional SOP (standard operating procedure) permits freezing of aqueous peptide formulations.
Once a pen is first activated, treat it as a working solution: keep it at 4 °C and limit excursions above ambient temperature. Both semaglutide and cagrilintide are acylated peptides whose albumin-binding C18/C20 fatty-diacid moieties tolerate refrigerated storage but degrade under repeated thermal cycling.
Avoid freeze-thaw cycles on activated pens entirely. For lyophilised research-grade comparator stock (for example, separately sourced cagrilintide for receptor-binding assays), standard practice is reconstitution with bacteriostatic water containing 0.9% benzyl alcohol, aliquoted single-use to prevent repeated thawing. Cagrilintide's reported plasma half-life of approximately 180 hours reflects in vivo albumin binding and should not be conflated with in vitro working-solution stability.
These notes are general guidance. Institutional SOPs and the supplier's batch insert take precedence. Researchers running parallel arms with the Body Pharm Semaglutide 6 Pen or benchmarking dual-agonist activity with the Body Pharm Tirzepatide 30 Pen should harmonise storage conditions across all arms to remove handling as a confounder.
Related Research Peptides Available in South Africa
For comparative in vitro work alongside the CagriSema 12 Pen, the Body Pharm range covers the main GLP-1 and incretin-axis comparators used in mechanism-of-action studies.
The Body Pharm Semaglutide 6 Pen is the standalone GLP-1R agonist arm researchers use to isolate the semaglutide contribution within the CagriSema combination. REDEFINE-1 reported −22.7% versus −16.1% weight change at 68 weeks for the combination over semaglutide monotherapy, which gives a clean quantitative basis for separating the cagrilintide contribution in parallel assay arms.
The Body Pharm Tirzepatide 30 Pen supplies the dual GIP/GLP-1 agonist comparator most frequently run in parallel against CagriSema, mirroring the REDEFINE-4 head-to-head design.
Retatrutide (GLP-1/GIP/glucagon triple agonist) and Tirsema (tirzepatide + semaglutide co-formulation) extend the comparator panel for labs profiling receptor selectivity and downstream cAMP/β-arrestin signalling across the full incretin class.
Frequently Asked Questions, CagriSema Research Peptide
Is CagriSema approved by SAHPRA in South Africa?
No. As of 2026, SAHPRA has not registered any cagrilintide+semaglutide combination product. Cagrilintide itself does not appear on published SAHPRA schedules because it has not completed the regulatory pathway in South Africa. Semaglutide is listed as a Schedule 4 prescription medicine when sold as a therapeutic. South African suppliers including MyAntidote, Ignite Muscle and Mzansi Weight Loss list the Body Pharm CagriSema 12 mg pen exclusively as a research chemical, not for human use.
How does CagriSema differ from semaglutide monotherapy?
CagriSema co-administers cagrilintide (a long-acting amylin analogue acting at CALCR+RAMP1/2/3) with semaglutide (a GLP-1R agonist), engaging two distinct satiety pathways because each receptor activates separate neuronal circuits. In REDEFINE-1, the 2.4 mg/2.4 mg combination produced approximately −22.7% mean body-weight change at 68 weeks versus −16.1% for semaglutide 2.4 mg monotherapy. Researchers running parallel arms typically pair this pen with the Body Pharm Semaglutide 6 Pen to isolate the cagrilintide contribution.
How is the Body Pharm 12 Pen format supplied?
Each prefilled pen contains 6 mg semaglutide plus 6 mg cagrilintide (12 mg total peptide) and is calibrated to dispense 0.25, 0.5, 0.75, 1.0 or 2.0 mg of each API per click, giving 0.5–4.0 mg total peptide per dose. Lot-specific certificate of analysis data is not published online and must be requested from the supplier.
Can CagriSema be used for human consumption?
No. All South African listings of the Body Pharm CagriSema 12 mg pen carry explicit "research chemical / not for human use" disclaimers. The product is not a SAHPRA-registered medicine. Labs planning any in vivo work should treat the combination as functionally Schedule 4-equivalent given semaglutide's scheduling.
What mechanistic comparators should be benchmarked alongside it?
The dual GIP/GLP-1 agonist Body Pharm Tirzepatide 30 Pen is the closest active comparator, mirroring the REDEFINE-4 head-to-head design. The Tirsema co-formulation and retatrutide extend the comparator set for labs profiling triple-agonism or stacked dual-agonist effects.
Where can South African researchers order this pen?
Order the Body Pharm CagriSema 12 Pen from JCSG.org with ZAR checkout and domestic tracked courier. Pair the order with the comparator pens linked above to complete a GLP-1R / dual-agonist / amylin-coagonist panel in a single procurement cycle. Verify purity independently via in-house HPLC or LC-MS before assay deployment to confirm batch potency.
